CD8A and neoplasm: Stroma with lower expression of immune markers (tumor-infiltrating lymphocytes and CD8+ T cells) could suppress the antitumor signatures and interfere with the penetration of immune cell infiltration into the tumor parenchyma, consistent with the poorer survival in the DMP-A immune phenotype (36–38).